Imatinib
About
Therapy type: Targeted therapy
Therapy strategy: Bcr-Abl inhibition, c-Kit inhibition, PDGF-R inhibition
Mappings
NCI Thesaurus: Imatinib (coding:ncit:C62035)
RxNorm: imatinib (coding:rxcui:282388, coding:omop:1304107)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (2) FDA (4) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Imatinib | |
| FDA (4) | BCR::ABL1 | Acute Lymphoblastic Leukemia | Imatinib | |
| EMA (1) FDA (2) | PDGFRA rearrangements | Myelodysplastic Syndromes | Imatinib | |
| EMA (1) FDA (2) | PDGFRB rearrangements | Myelodysplastic Syndromes | Imatinib | |
| FDA (2) | not KIT p.D816V | Aggressive Systemic Mastocytosis | Imatinib | |
| EMA (1) FDA (2) | FIP1L1::PDGFRA | Chronic Eosinophilic Leukemia, NOS | Imatinib | |
| EMA (2) FDA (2) | CD117 + | Gastrointestinal Stromal Tumor | Imatinib | |
| FDA (2) | FIP1L1::PDGFRA | Gastrointestinal Stromal Tumor | Imatinib | |
| EMA (2) | not BCR::ABL1 | Acute Lymphoblastic Leukemia | Imatinib | |
| EMA (1) | PDGFRA rearrangements | Myeloproliferative Neoplasm | Imatinib | |
| EMA (1) | PDGFRB rearrangements | Myeloproliferative Neoplasm | Imatinib |